OTC deficiency represents 55%–60% of all UCD patients, followed by ASL (15%–20%), ASS (10%–15%) and CPS1 (5%–10%) deficiencies.2, 3, 4. The gene discussed is CPS1; the disease is ornithine carbamoyltransferase deficiency.